InVentiv opens U.K. hub as EU demand climbs

CRO giant inVentiv Health ($VTIV) has opened a one-stop shop in the London suburbs, consolidating three of its U.K. operations into one all-encompassing office to better meet European demand.

The new space in Maidenhead, U.K., brings inVentiv's clinical, commercial and consulting businesses all under one roof, allowing for collaboration and knowledge-sharing among its 180 employees at the site. InVentiv is betting that setup will allow it to better serve its growing client base in Europe, and the CRO is expecting to expand the Maidenhead site over the next few years, leaving room for more workers to come.

CEO Paul Meister said the new site is "an important milestone in the expansion of our company as it allows us to successfully meet the needs of our clinical, commercial and consulting workforce. InVentiv's global footprint continues to expand, and the Maidenhead office will play a central role."

The Massachusetts-headquartered CRO has been growing in every direction this year, spending money on new technology, novel partnerships and a stake in the biosimilars market.

InVentiv is buidling up its eClinical presence with a just-launched online network of physicians for trials and a separate agreement with PatientsLikeMe that allows the site's more than 200,000 members to view and apply for relevant studies. And the CRO is deepening its consulting services with the September establishment of Breakaway Policy Strategies, a joint venture offering policy advice to drugmakers. Furthermore, inVentiv has a deal with Oncobiologics to run trials and get biosimilars of some of world's top-selling treatments onto the market.

- read the announcement

Suggested Articles

WuXi AppTec has cut the ribbon on its expanded Laboratory Testing Division in New Jersey as it looks to boost its integrated testing service portfolio.

St. Jude, Microsoft and DNAnexus have created a data-sharing and analysis platform to help accelerate pediatric cancer research.

The money will be used to expand its footprint in both China and the U.S., including a new R&D operation in Boston.